Galapagos NV
26.02
24-December-24 07:54:02
15 minutes delayed
Stocks
+0.22
+0.85%
Today's range
25.85 - 26.16
ISIN
BE0003818359
Source
Cboe
-
Galapagos appoints Paul Stoffels as Chief Executive Officer
26 Jan 2022 16:01:00 By Nasdaq GlobeNewswire
-
18 Jan 2022 16:01:00 By Nasdaq GlobeNewswire
-
Galapagos creates new subscription right plan
13 Jan 2022 16:01:00 By Nasdaq GlobeNewswire
-
Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
06 Jan 2022 09:30:00 By Nasdaq GlobeNewswire
-
Galapagos increases share capital through subscription right exercises
03 Dec 2021 16:01:00 By Nasdaq GlobeNewswire
-
22 Nov 2021 16:01:00 By Nasdaq GlobeNewswire
-
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
15 Nov 2021 10:45:07 By Nasdaq GlobeNewswire
-
Galapagos reports commercial and operational progress at Q3 financial results
04 Nov 2021 17:01:00 By Nasdaq GlobeNewswire
-
04 Oct 2021 16:01:00 By Nasdaq GlobeNewswire
-
04 Oct 2021 01:01:00 By Nasdaq GlobeNewswire
-
Galapagos increases share capital through subscription right exercises
20 Sep 2021 16:01:00 By Nasdaq GlobeNewswire
-
17 Sep 2021 07:15:00 By Nasdaq GlobeNewswire
-
Galapagos announces planned retirement of CEO
30 Aug 2021 16:01:00 By Nasdaq GlobeNewswire
-
Galapagos reports H1 financial results with refocused pipeline and operational progress
05 Aug 2021 16:01:00 By Nasdaq GlobeNewswire
-
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
14 Jul 2021 16:01:00 By Nasdaq GlobeNewswire
-
14 Jul 2021 16:01:00 By Nasdaq GlobeNewswire
-
10 Jul 2021 05:10:00 By Nasdaq GlobeNewswire
-
Galapagos announces departure of CSO Piet Wigerinck later this year
22 Jun 2021 16:01:00 By Nasdaq GlobeNewswire
-
Galapagos increases share capital through subscription right exercises
07 Jun 2021 16:01:00 By Nasdaq GlobeNewswire
-
SELECTION study on filgotinib in ulcerative colitis published in The Lancet
04 Jun 2021 01:01:00 By Nasdaq GlobeNewswire